Look out Lucentis and Eylea: New radiotherapy for wet AMD threatens anti-VEGF – Clinica
This article was originally published in Scrip
According to Clinica Medtech Intelligence, a non-invasive, one-time radiotherapy procedure developed by an emerging Californian company for treating wet age-related macular degeneration could threaten to stymie the double-digit growth that drug giants Novartis and Roche have seen in sales of their market-leading anti-VEGF therapy Lucentis.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.